This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effects of Lycopene on High Risk Prostatic Tissue

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Peter Gann, University of Illinois at Chicago Identifier:
First received: September 27, 2011
Last updated: December 1, 2015
Last verified: December 2015
The purpose of this research study is to compare the effects of a lycopene supplement made from tomatoes to a placebo (a capsule with no active ingredients) in men who have abnormal cells in the prostate, but have not yet had cancer detected. This study will allow us to see if taking lycopene for six months leads to favorable changes in abnormal prostate tissue and in chemicals measured in the blood that go along with a higher risk of developing cancer.

Condition Intervention Phase
Intraepithelial Prostatic Neoplasia Prostatic Neoplasms Drug: Lycopene 30mg Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: R01 CA90759: The Effects of Lycopene on High Risk Prostatic Tissue

Resource links provided by NLM:

Further study details as provided by Peter Gann, University of Illinois at Chicago:

Primary Outcome Measures:
  • Tissue Biomarkers [ Time Frame: baseline and 6 months ]
    We will use conventional immunohistochemistry and computer-based image analysis to test the hypothesis that the lycopene supplements alter the expression of proteins marking the status of proliferation, differentiation, cell regulation and apoptosis in high-risk tissue.

  • Changes in Serum Biomarkers [ Time Frame: baseline and 6 months ]
    Change in serum lycopene, umol/L

Secondary Outcome Measures:
  • Changes in Nuclear Morphometry [ Time Frame: baseline and 6 months ]
    We will use a computerized image analysis system designed for the chemoprevention setting to test the hypothesis that the antioxidants cause a favorable change in a nuclear morphometry index based on nuclear size, shape and chromatin texture.

Enrollment: 66
Study Start Date: February 2006
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lycopene
Lycopene 30 mg/day
Drug: Lycopene 30mg
Lycopene 30 mg.
Other Name: Lyco-Mato
Placebo Comparator: Placebo
Drug: Placebo
Other Name: Sugar Pill


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male
  • Have a history of prostate biopsy indicating HGPIN without cancer within 2 years prior to registration. At least 4 weeks must have elapsed between the last biopsy and the biopsy used for baseline data.
  • Have an AUA symptom score <=25 at time of registration.
  • Refrain from taking lycopene, selenium, vitamin E, or other antioxidant supplements within 1 month of randomization. Participants must agree to refrain from taking non-study dietary supplements while on study
  • Refrain from taking exogenous hormones, drugs affecting hormone metabolism, or specified non-prescription substances (e.g. saw palmetto, PC-Spes) taken to affect the prostate within 1 month of registration. Patients must also agree to refrain from taking the non-prescription substances while on study
  • Be willing to limit intake of lycopene-containing foods while on study
  • Have no prior cancer (except basal cell or squamous cell skin cancer) or complete remission for at least 5 years
  • Be ambulatory, capable of self-care and able to carry out light or sedentary work
  • Have a dietary fat intake of 23-48% of calories
  • Participant's physician recommends repeat biopsy 4-6 months after randomization

Exclusion Criteria:

  • No repeat biopsy planned
  • Not willing to change diet
  • Have a diagnosis of prostate cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01443026

United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
Jesse Brown VA Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
University of Illinois at Chicago
National Cancer Institute (NCI)
Principal Investigator: Peter H Gann, MD, ScD University of Illinois at Chicago
  More Information

Responsible Party: Peter Gann, Professor and Director, Division of Pathology Research, University of Illinois at Chicago Identifier: NCT01443026     History of Changes
Other Study ID Numbers: 2005-0828
R01CA090759 ( U.S. NIH Grant/Contract )
Study First Received: September 27, 2011
Results First Received: April 17, 2014
Last Updated: December 1, 2015

Keywords provided by Peter Gann, University of Illinois at Chicago:
Intraepithelial Prostatic Neoplasia
Prostatic neoplasms
Male urogenital disease

Additional relevant MeSH terms:
Prostatic Neoplasms
Prostatic Intraepithelial Neoplasia
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Radiation-Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents processed this record on September 21, 2017